The importance of vitamin D for bone health is well established, but the role of vitamin D beyond the skeletal system has been under debate for decades ([@bib110]). In recent years, it has become apparent that the vitamin D receptor (VDR) is expressed in most cells, and that multiple tissues have the ability to convert the primary circulating form of vitamin D into the active form ([@bib12]), implying that extra-skeletal effects of vitamin D are likely.

While typically thought of as 'vitamin\', it may be more appropriate to regard the primary circulating form, 25-hydroxyvitamin D (25OHD), as a pre-hormone and the primary active form, 1,25-dihydroxyvitamin D (1,25(OH)~2~D), as a *hormone*. It has been previously recognised that mutations in genes involved in response to hormones, their metabolism or actions may affect the prognosis of disease and thus act as modifiers. Correspondingly, 1,25(OH)~2~D binds to the VDR (a ligand-dependent transcription factor) and polymorphisms in the *VDR* gene have been shown to modify the activity of this VitD--VDR complex ([@bib4]): for example, rs11568820 is situated in the *VDR* promoter region and can influence transcriptional activity ([@bib132]), while rs2228570 affects the translational start site ([@bib117]). Therefore, it is hypothesised that not only vitamin D status but also expression and structure of *VDR* determine molecular actions, and can potentially modify cancer risk and survival ([@bib35]; [@bib64]; [@bib137]). The VitD--VDR complex has the ability to exert downstream biological effects; amongst others, it can regulate the expression of multiple target genes, including several with anti-tumour properties ([@bib96]). Moreover, polymorphisms in the *VDR* gene have been linked to cancer risk, including prostate ([@bib108]), breast ([@bib69]), skin and bowel ([@bib53]; [@bib130]; [@bib99]), and VDR expression has been linked to survival in prostate and breast cancer ([@bib9]; [@bib47]; [@bib25]). Unlike highly variable environmental exposures (sunlight, diet and supplements) or seasonally varying 25OHD levels ([@bib56]), genetic variants are constant, present since conception and cannot be modified by the disease; thereby removing reverse causation concerns.

Three aspects further strengthen the case for understanding the associations between vitamin D and cancer outcomes: first, cancer incidence and mortality are increasing ([@bib19]); second, vitamin D deficiency is common worldwide among otherwise healthy individuals ([@bib49]; [@bib138]), and particularly among cancer patients ([@bib18]; [@bib28]; [@bib100]; [@bib122]; [@bib137]), and third, vitamin D deficiency is a modifiable risk factor; based on the studies that report an association between vitamin D deficiency and poorer cancers outcomes. Unsurprisingly, it has been proposed that vitamin D may have potential value as an adjuvant chemotherapeutic agent, particularly since vitamin D supplements are cheap, safe and readily available ([@bib80], [@bib81]; [@bib26]; [@bib45]; [@bib137]).

Here we present a systematic review and meta-analysis examining the role of vitamin D on cancer progression and survival. We conducted a comprehensive evaluation of the literature that examines the associations between cancer outcomes and genetic factors involved in the vitamin D pathway, in addition to circulating 25OHD concentration. Focus on vitamin D-related genetic variation allowed us to partially mitigate against potential confounding or reverse causation, biases that typically limit implications of findings from observational vitamin D studies.

Materials and methods
=====================

Literature search
-----------------

We performed a systematic literature review and meta-analysis following PRISMA guidelines ([@bib75]). The electronic databases PubMed ([@bib79]), EMBASE ([@bib27]), and Web of Science ([@bib55]) were searched up to week 3, November 2015. We searched for studies that examined the association between cancer outcomes and (i) measured vitamin D levels and (ii) genetic factors known to affect vitamin D metabolism or pathways. A list of search terms was compiled using a number of core papers in the field. For cancer outcomes, we included a combination of terms: cancer, neoplasm, malignant, malignancy with survival, outcome, prognosis, mortality, death, recurrence. For vitamin D levels, we included terms: 25-hydroxyvitamin D, calcidiol and 25OHD; for vitamin D receptor, and for commonly studied variants, we searched for: vitamin D receptor, *VDR*, rs1544410, *BsmI*, rs10735810, rs2228570, *FokI*, rs7975232, *ApaI*, rs11568820, *Cdx-2*, rs2282679, rs12785878, rs10741657 and rs6013897. Finally, we also included variation in genes related to vitamin D synthesis, transport or metabolism: 1-*α*-hydroxylase, *CYP27B1*, 25-hydroxylase, *CYP2R1*, 24-hydroxylase, *CYP24A1*, vitamin D binding protein, 27-hydroxlyase and *CYP27A1*. Genetic variants beyond those explicitly searched for were only included if previously shown to affect vitamin D metabolism. We considered all human research full text articles, with no restriction on language or article type. Bibliographies of retrieved papers and previous reviews were hand-searched to identify other relevant studies.

Selection criteria and selection of relevant studies
----------------------------------------------------

Study inclusion 'PICO\' criteria were as follows: (i) participants: individuals of any age who received a diagnosis of cancer; (ii) intervention/Exposures: assessment of vitamin D status or genetic factors known to affect vitamin D concentration, metabolism or pathways; (iii) comparators: study reports a quantitative association between cancer outcome and either vitamin D status (e.g., concentration, quartiles, low/high levels) sampled at most 1 year prior to the diagnosis, or any germline genetic variation or gene expression in normal tissue; and (iv) Outcome: cancer-specific or all-cause mortality, or disease progression (e.g., disease-free survival, local recurrence or metastasis). Observational retrospective and prospective cohorts were included.

In relation to patients, exclusion criteria were: (i) pre-cancerous lesions, and (ii) mixed-cancer cohort without site-specific reporting; in relation to exposures: (iii) vitamin D intake and supplementation, (iv) acquired non-germline mutations or tumour gene expression, and (v) predicted vitamin D status; in relation to outcomes: (vi) prognostic markers such as Prostate Specific Antigen or Breslow thickness, (vii) population cancer mortality rates; in relation to study/publication type: (viii) ecological studies, and (ix) reviews, editorials, case reports, conference abstracts and nonclinical publications. If the same patient cohort was reported on more than once, we used the highest quality, largest sample size or most recent publication. Article titles and abstracts were screened for eligibility, independently by two authors (PVS and LZ or FOS). Disagreements were resolved by discussion and review of full text.

Data extraction
---------------

The data extraction was performed by a single investigator (PVS or FOS) using the predefined data fields and extraction was cross-checked by a second investigator in its entirety (FOS or PVS). The data from eligible studies were extracted using a tailored data extraction form that included the following information: first author, publication year, location or ethnicity of patients, sample size, mean age, gender, cancer site (subtype/histology where relevant), cancer stage, any interventions (e.g., chemotherapy), vitamin D exposure studied and important meta-data (time of sampling, mean/median 25OHD values or range for categories being compared; SNP position, name and rs ID, genotypes compared and model: additive, recessive or dominant), covariates considered, details of outcomes studied, and follow-up time. Finally, hazard ratios (HR) and 95% confidence intervals (95% CIs) adjusted for the maximum number of confounding variables were extracted. We preferentially focused on cancer-specific mortality, but if these data were not available, all-cause mortality was used instead. Relative risk estimates (RR) or adjusted odds ratios (OR) were extracted where HR were not given and used in meta-analysis ([@bib105]). Study authors were contacted to provide additional information where needed.

Quality assessment
------------------

The methodological quality of all studies included in the systematic review was performed using the Newcastle-Ottawa Quality Assessment Scale (NOS; [@bib126]). Two investigators (PVS and FOS) applied predefined NOS criteria to each study to generate summary quality judgement. The risk of bias was considered 'low\' for studies with score of 7 or 8; 'unclear\' for score of 5 or 6, and 'high\' for score of 4 or lower.

Exposure assessment
-------------------

The association between circulating 25OHD and outcomes was summarised in meta-analyses by comparing the risk in the highest to the lowest reported category. The majority of studies used vitamin D categories such as quartiles or tertiles. To enable inclusion of studies that used 25OHD as a continuous variable, we sought to transform the 'continuous HR\' into a 'HR per 10 ng ml^−1^\' ([Box 1](#box1){ref-type="boxed-text"}).

### Genetic factors

For SNPs, the rs number naming convention was typically used in the paper and some recoding was needed to ensure that uniform reference system was followed. For example, where a restriction fragment length polymorphism was referenced, the mutation and risk allele were recoded (e.g., *FokI f* allele was converted to the rs2228570 *T* allele). The genome browser ENSEMBL (80 GRCh38.p2) was used to determine if alias names existed (e.g., *FokI,* rs10735810 and rs2228570 are the same variant). HR values were inverted where needed, so that the same allele acted as the reference. Where additive models were used, the HR values were squared in order to approximate the HR value for comparison between two homozygotes.

Statistical analysis
--------------------

We conducted meta-analyses for a range of exposure-outcome pairs by cancer site and across all sites. A meta-analysis was performed if at least two studies considered the same exposure-outcome pair. The same study may have been included multiple times in different meta-analyses if it reported on multiple subpopulations, outcomes, and/or exposures. The extracted HRs and 95% CIs were used to calculate the pooled HR estimates. The standard errors (s.e.) were used to calculate weighting for each study. The DerSimonian and Laird random-effects model was used to calculate pooled HR because of the *a priori* expected heterogeneity between studies, due to differences among populations and methodological dissimilarities between studies; most notably, different definition of 25OHD categories. All analyses were performed in R ([@bib95]), and the R-package 'metafor\' was used for meta-analyses ([@bib120]). *P*-value \<0.05 was considered statistically significant.

In order to assess the impact of study quality on results, meta-analyses were rerun (i) after exclusion of studies at high risk of bias, (ii) limited to studies at low risk of bias only, (iii) limited to studies that looked at cancer-specific mortality, (iv) excluding studies that used 25OHD as a continuous variable, and (v) excluding studies that reported RR or OR. The *I*^2^ statistic was calculated to quantify the degree of heterogeneity between studies and assess impact on the meta-analysis ([@bib48]). To further explore this issues arising due to the striking differences in 25OHD category definition, we conducted a stratified analysis ([@bib17]) according to: (vi) the difference in mean/median 25OHD between 'high\' and 'low\' categories compared (below or ⩾20 ng ml^−1^), and (vii) the degree of deficiency in 'low\' category (mean/median 25OHD concentration below or ⩾12.5 ng ml^−1^). Publication and selection bias was investigated by checking for asymmetry in the funnel plots and running the Egger\'s regression test ([@bib104]).

Results
=======

A flowchart illustrating study selection is shown in [Figure 1](#fig1){ref-type="fig"}. After removal of duplicates, the search yielded 3070 potential articles. Irrelevant articles were eliminated after screening titles (*N*=2708) or abstracts (*N*=262). One hundred full-texts were considered for inclusion and assessed for eligibility and 19 were excluded. Finally, 81 articles were kept for the systematic review and 64 of these were included in the meta-analysis. The main characteristics of included studies are summarised in [Table 1](#tbl1){ref-type="table"} and [Table 2](#tbl2){ref-type="table"}.

Assessment of included studies
------------------------------

The risk of bias assessment revealed that 35 studies (43%) had a low risk of bias, 35 (43%) had an uncertain, and 11 (14%) had a high risk of bias. The risk of bias assessment summary per each domain is shown in [Supplementary Figure S1](#sup1){ref-type="supplementary-material"} and individual study scores in [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}. Sixty-four studies were included in the meta-analysis, with a total of 44 165 patients. Most studies were conducted in the USA (*N*=24) and Europe; breast cancer was most commonly studied (*N*=15), followed by nine studies (each) on prostate cancer and colorectal cancer. In total, 157 HR estimates for a range of exposure-outcome pairs were included in meta-analyses: 77 estimates (from 41 studies) for association with 25OHD, and 80 estimates (from 27 studies) relating to genetic factors. Separate estimates were extracted for different patient subgroups (e.g., different type of haematological malignancy ([@bib26])), different exposures (e.g., multiple polymorphisms ([@bib137])), or different outcome (i.e., survival or disease progression ([@bib68])). No patients were included more than once in meta-analysis, as separate meta-analyses have been conducted for each exposure-outcome pair. Very large differences were observed in definition of vitamin D categories being compared. For example, the median 25OHD concentration was 18.26 ng ml^−1^ in the 'high\' category in one study, ([@bib137]) yet this was actually lower than the median (19.7 ng ml^−1^) in the 'low\' category in another study ([@bib45]). The variety of vitamin D categories, cutoffs and means/medians used are presented in [Figure 2](#fig2){ref-type="fig"} and [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}.

Meta-analysis of 25OHD studies
------------------------------

### Circulating vitamin D and survival

Forty-eight estimates from 38 studies were included in the meta-analysis of 25OHD and survival (17 studies (45%) examined cancer-specific mortality), comprising in total 24 013 cancer patients. Twelve cancer types were represented: breast, haematological, head and neck, colorectal, lung, prostate, skin, pancreatic liver, gastric, kidney and ovarian cancers. Overall, a significantly reduced risk of death was observed when comparing those with high to those with low vitamin D levels; meta-analysis HR=0.74, 95% CI=0.66 to 0.82 ([Figure 3](#fig3){ref-type="fig"}). The same significant trend was also observed in subgroup meta-analysis for breast (HR=0.75, 95% CI=0.56--0.95), haematological (HR=0.59, 95% CI=0.42--0.77) and colorectal cancers (HR=0.75, 95% CI=0.60--0.90). There was also a non-significant trend towards better survival with increased 25OHD observed in the subgroup analysis for prostate, skin, head and neck cancers. Virtually no change in direction or significance in overall effect was observed in sensitivity analyses when excluding studies at high risk of bias (HR=0.73, 95% CI=0.65--0.80), focusing on the studies at low risk of bias only (HR=0.72, 95% CI=0.63--0.81), excluding studies that used continuous 25OHD (HR=0.73, 95% CI=0.65--0.80), limited to cancer-specific mortality studies only (HR=0.75, 95% CI=0.65--0.84), or to studies that strictly reported HR (HR=0.74, 95% CI=0.66--0.82). The same was true after selection of studies where the difference in mean/median between high and low categories being compared was over or below 20 ng ml^−1^; (HR=0.70, 95% CI=0.60--0.81, and HR=0.71, 95% CI=0.55--0.87, respectively), or when stratifying by the lower category mean/median below or greater than 12.5 ng ml^−1^ (HR=0.76, 95% CI=0.64--0.88, and HR=0.61, 95% CI=0.47--0.75, respectively) (for sensitivity analysis please see supplementary material).

### The relationship between circulating vitamin D level and disease progression

Twenty-three studies investigated the association between circulating 25OHD and disease progression; from these studies 29 estimates were included in our meta-analysis comprising in total 14 307 patients with breast, haematological, head and neck, colorectal, prostate, skin, pancreatic, or ovarian cancer. Higher circulating vitamin D was associated with a significant reduction in disease progression for all cancers combined (HR=0.84, 95% CI=0.77--0.91; [Figure 4](#fig4){ref-type="fig"}); this was also observed in subgroup meta-analysis of breast (HR=0.66, 95% CI=0.45--0.88), haematological (HR=0.75, 95% CI=0.61--0.88) and skin cancer (HR=0.77, 95% CI=0.58--0.97). Findings remain fundamentally unchanged after exclusion of studies at high risk of bias (HR=0.82, 95% CI=0.74--0.90), limited to studies at low risk of bias only (HR=0.80, 95% CI=0.70--0.90) or excluding studies that used continuous 25OHD (HR=0.81, 95% CI=0.73--0.90), or limited to studies that strictly reported HR (HR=0.84, 95% CI=0.77--0.91). The same was true after selection of studies where the difference in mean/median between high and low categories being compared was over or below 20 ng ml^−1^; (HR=0.81, 95% CI=0.72--0.90, and HR=0.75, 95% CI=0.55--0.95, respectively), or when stratifying by the lower category mean/median below or greater than 12.5 ng ml^−1^ (HR=0.84, 95% CI=0.71--0.97, and HR=0.77, 95% CI=0.62--0.92, respectively) (for sensitivity analysis please see supplementary material.

Vitamin-D-related genetic variation
-----------------------------------

### VDR and other vitamin D pathway SNPs and survival

Twenty-one studies investigated the association between vitamin-D-related genetic variation and survival; 10 (48%) examined cancer-specific mortality. By far, the most commonly studied were polymorphisms in *VDR* gene, particularly rs2228570 (*FokI),* rs1544410 (*BsmI),* rs731236 *(TaqI),* rs11568820 *(Cdx2)*, and *rs*7975232 (*ApaI)*. In meta-analysis, rs1544410 *TT/TC* genotypes were associated with worse survival compared to CC genotype (HR=1.40, 95% CI=1.05--1.75; [Figure 5](#fig5){ref-type="fig"}). The same direction of the effect was observed in the sensitivity analyses after exclusion of studies with NOS\<7 ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}) and those reporting on cancer-specific mortality, but the association was no longer significant ([Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). In lung cancer patients, a poorer outcome was observed to be associated with rs2228570 *TT/TC* carriers (HR=1.29, 95% CI=1.00--1.57) and a consistent albeit non-significant association was found across all cancers (HR=1.26, 95% CI=0.96--1.56). A significant association was observed with rs731236 *(Taq1)* variant when limited to studies at low risk of bias (NOS score ⩾7; HR=0.79, 95% CI=0.62--0.95, [Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). Other genetic factors were investigated in at most three original studies and no other statistically significant results were observed.

### VDR and vitamin D pathway SNPs and disease progression

Ten studies examined the effect of genetic variation on disease progression ([Figure 6](#fig6){ref-type="fig"}; for sensitivity analysis see [Supplementary Figure S6](#sup1){ref-type="supplementary-material"}). In meta-analysis of three studies with a total of 1588 patients, it was observed that *rs*7975232 *AA* carriers had significantly worse survival than CC carriers (HR=1.29, 95% CI=1.02--1.56). Additionally, a suggestive association was observed for vitamin D binding protein variant *rs2282679* (HR=1.22, 95% CI=0.99--1.46) in meta-analysis of two studies.

Testing for publication bias and study heterogeneity
----------------------------------------------------

There was some evidence of heterogeneity between studies in meta-analysis of 25OHD and some evidence of publication bias ([Supplementary Figures S7 and S8](#sup1){ref-type="supplementary-material"}). A non-insignificant degree of heterogeneity and evidence of publication bias were observed in some subgroup analysis. Heterogeneity was observed for subgroup analysis of rs1544410, rs7975232, rs2228570 and rs731236, as well as for some individual cancer types while publication bias was observed for rs1544410, rs2228570 and rs731236 ([Supplementary Figures S7 and S8](#sup1){ref-type="supplementary-material"}).

Studies not included in meta-analysis
-------------------------------------

Seventeen papers were excluded from the meta-analysis, but their findings were nonetheless considered ([Table 2](#tbl2){ref-type="table"}). Eight studies report improved overall and/or progression-free survival among those with higher 25OHD concentration ([@bib122]; [@bib124]; [@bib91]; [@bib33]; [@bib8]; [@bib23]; [@bib44]; [@bib86]) and one study found no association between 25OHD and incidence of metastases ([@bib84]). Seven studies investigated genetic variants and outcome (median sample size: 66). One study reported that the rs731236/rs2228570 (*TaqI-FokI, TTFf/TtFf)* haplotype was significantly associated with reduced overall survival (HR=1.81, 95% CI=1.23--3.48, *P*=0.04) ([@bib116]): suggestive associations were reported between progression-free survival and rs731236 (*AA*) genotype in prostate cancer ([@bib36]) and rs2228570 *TT* genotype in breast cancer ([@bib134]), while there was no association found between rs2228570 and paediatric ALL ([@bib58]). No association was observed between rs1544410 and breast cancer outcome ([@bib131]). There was a suggestive association between platelet VDR expression and survival in ovarian cancer ([@bib101]). Finally, low vitamin D binding protein (DBP) levels were found to be predictive of lung cancer death ([@bib115]).

Discussion
==========

This is the first systematic review with meta-analysis that examines the relationship between cancer outcomes and variation in vitamin D pathway genes, and also by far the largest review on vitamin D status and cancer outcome. Our review suggests that higher circulating vitamin D in cancer patients is associated with a 26% lower rate of death and a 16% lower rate of disease progression. The clear association with survival was also observed in site-specific analyses of breast, haematological and colorectal cancers, while an association with reduction in disease progression was also found in those diagnosed with breast, haematological and skin cancer.

Establishing a causal relationship between vitamin D status and cancer progression is challenging because risk factors associated with cancer outcome are often also associated with vitamin D deficiency. For example, the association between 25OHD and improved survival observed in the original studies might be due to 25OHD being a marker of healthier lifestyle (i.e., healthier diet containing more fish; physical activity and spending time outdoors). However, evidence that genetic factors linked to vitamin D metabolism and pathways impact upon cancer survival may be used to counter such concerns and support a causal link. In our meta-analysis, we found evidence of an association between the *VDR* gene variants with functionally characterised effects and cancer outcome. Forty percent higher rate of death was observed in *TT* carriers at rs1544410 locus and 26% higher rate in *TT* carriers at rs2228570, while 29% increased risk of disease progression was observed in *AA* carriers at *rs*7975232 and 22% in *GG* carriers at GC locus.

Evidence from biological studies support a role for these polymorphisms in modulating vitamin D biology. For example, rs2228570 has been shown to affect the translational start site of 1,25(OH)~2~D and hence its downstream effects ([@bib117]), while rs1544410 and *rs*7975232 have been associated with changes in *VDR* messenger RNA expression ([@bib103]; [@bib117]). We hypothesise that interactions between mutations in the vitamin D pathway and vitamin D status exist, and that this interaction could have a critical role in cancer prognosis. Indeed, Han *et al* ([@bib43]) have shown an interaction between vitamin D intake and rs1544410 polymorphism on cancer risk, and we and others have previously shown a modification of the relationship between vitamin D intake or status and cancer outcome by other *VDR* variants, thus suggesting an interaction of genetic and environmental factors ([@bib64]; [@bib109]; [@bib3]; [@bib137]). In conjunction with the strong associations observed for vitamin D status, evidence from genetic studies further supports an important role of vitamin D in cancer progression.

Few studies to date have analysed the associations between *VDR* or vitamin D pathway genetic variants and cancer outcomes, and no meta-analyses have been published to date. A review by Kostner *et al* ([@bib61]) concluded that associations between *VDR* polymorphisms and cancer prognosis are strongest for prostate cancer (rs2228570), breast cancer (rs1544410, rs731236) malignant melanoma (rs1544410), and renal cell carcinoma (rs731236) but did not perform meta-analysis on these data.

Interestingly, Afzal *et al* ([@bib1]) have employed principles of Mendelian randomization in a study comprising 95 766 participants and found that variation in genes involved in vitamin D and 25OHD synthesis *(DHCR7* and *CYP2R1)* were associated with both all-cause and cancer mortality, supporting a causal role of vitamin D. To date, there are no published findings from randomised controlled trials (RCT) assessing the effect of vitamin D supplementation [@bib2]. Meanwhile, the data on cancer mortality from RCTs conducted in the general population can offer some insight; most notably, a Cochrane review of randomised studies comparing vitamin D supplements to placebo identified a significant reduction in cancer mortality in those taking vitamin D supplements (HR=0.88, 95% CI=0.78--0.98; [@bib11]).

A major issue that is typically taken poor notice of in vitamin D meta-analyses---namely, a very large variability in vitamin D category definition amongst studies, is for the first time being highlighted and transparently shown in our review. Vitamin D categories differed in level as well as range---as a result, large heterogeneity in exposure definition occurred and study point-estimates are difficult to compare: it is, for example, unsurprising that the reported effect per 20 ng ml^−1^ is greater than effect per 5 ng ml^−1^ increase. Therefore, there is a need for a consensus in category definition and reporting of effect sizes: future original studies should report effect sizes using internationally agreed cutoffs, such as those given by the Institute of Medicine, solely or in addition to study-specific cutoff values chosen. Generally, variability in exposure categories results in a more heterogeneous estimates and is likely to increase statistical uncertainty and hence bias results towards the null. Nonetheless, our summary findings remain largely unchanged when the analysis was limited according to the difference in 25OHD between the compared groups.

There are some additional limitations of the present work. First, a number of relevant studies were published after the time limits stipulated in our search strategy and so are not included in our meta-analysis. Some such papers support the conclusions presented here ([@bib13]; [@bib30]; [@bib31]; [@bib77]; [@bib87]; [@bib133]; [@bib135]), while others reported no association between circulating vitamin D and cancer outcome ([@bib118]; [@bib2]; [@bib21]; [@bib71]).

Second, various assays were used for 25OHD measurement in the different studies, while 25OHD was also sampled at variable timepoints, including pre-diagnosis, before treatment and after treatment, which may impact the results. Also, in disease progression studies, different outcome definitions were used for example, disease-free survival, local or distant recurrence.

In the present study, results for all cancers combined are given, in addition to site-specific findings, we yet fully acknowledge that cancer is a heterogeneous disease. However, numerous studies have shown involvement of vitamin D on key hallmarks of cancer, many of which are common to all cancers; preclinical studies demonstrate effects on cell cycle arrest, cell adhesion, differentiation, proliferation, tumour angiogenesis, and apoptosis in human cancer cell lines ([@bib102]; [@bib14]; [@bib62]; [@bib22]; [@bib60]; [@bib52]; [@bib111]), while reduction in cancer proliferation has been shown in carcinogen-exposed rats ([@bib76]) and cancer phenotypes are more commonly observed in vitamin D receptor (*VDR*) knockout mice ([@bib139]). Nevertheless, the heterogeneity in pooled results between different cancer types and the small number of studies for certain cancers limits the strength of the current study in demonstrating an association between circulating 25-hydroxyvitamin D and total cancer survival.

Next, in reporting the impact of genetic variation on outcome, we acknowledge that ethnic differences in VDR variation exist, which might interfere with the findings from genetic studies, as ethnicity is directly linked to the skin type and vitamin D synthesis. Meanwhile, VDR variants may interact with circulating 25OHD to impact outcome, yet only a small number of studies examined these putative gene--environment interactions. Finally, we observed some evidence of heterogeneity and publication bias overall; however, findings from sensitivity analysis were highly consistent and supportive of main findings.

Despite these limitations, the present work includes a novel meta-analysis, investigating the association between vitamin D-related genetic variation and cancer outcome, in addition to a ∼50% larger meta-analysis of circulating 25OHD and cancer outcome compared to a previous review ([@bib65]). Moreover, stringent quality assessment of original studies and corresponding sensitivity analysis were conducted and strikingly inconsistent 25OHD category definitions were addressed in stratified analysis.

In conclusion, the consistent evidence across the studies presented in the current review demonstrates a clear and strong association between low baseline vitamin D levels and poorer cancer survival. The associations between vitamin D-related genetic variants and cancer survival support an interpretation that vitamin D may play an important role in influencing cancer outcome. However, a causal link cannot be conclusively established from observational studies; hence, well-designed and adequately powered RCTs are needed to evaluate the clinical application of vitamin D in augmenting standard follow-up and adjuvant chemotherapy regimens. Understanding the mechanism of action of genetic factors promises to provide further insight into biological determinants of response to treatment and could help inform prognosis.
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![**PRISMA Flowchart of the study selection process.**Two studies used the same prostate cancer cohort but one reported on circulating 25OHD and the other on genetic variants, and so both were retained. ([@bib50], [@bib51]) Three publications used the same initial cohort of lung cancer patients but two reported on different subpopulations of patients (according to disease stage) and so were retained, ([@bib140]; [@bib46]), while a third reported on different exposures to the first two and so was also retained ([@bib141]). Finally, four studies reported on the same melanoma patient cohort ([@bib80], [@bib81]; [@bib33]; [@bib20]) (one paper scored lower in NOS scoring was excluded ([@bib33]), while the remaining three, which reported different exposure or outcomes were retained. ^§^Only a single study reported impact of circulating vitamin D-binding protein levels on outcome and so could not be included in the meta-analysis. \*Includes only exposures and outcomes included in MA. Articles may report on multiple exposure-outcome pairs hence the sum of the pairs is greater than the number of articles included. For example, several papers studied the effect of more than one SNP for example, Zgaga *et al*, ([@bib137]), while many papers studied the impact on both overall survival or progression-free survival for example, Lohman *et al* ([@bib68]). However, where multiple estimates were extracted, no patient was included more than once for a certain exposure or outcome. † Study authors were contacted to provide HR, RR or OR when not reported; 13 did not respond. ¥ One study ([@bib122]) used the same breast cancer cohort as a later, larger study ([@bib123]) and as both had the same NOS score, the newer study was included. 25OHD: 25-hydroxyvitamin D; DBP: vitamin D binding protein; HR: hazard ratio; PSA: prostate specific antigen; WOK: Web of Knowledge.](bjc201744f1){#fig1}

![**Large variation in definition of vitamin D categories in studies included in systematic review.**Where not given in the paper, median 25OHD concentration for categories compared was requested from study authors and if not subsequently available was approximated. Approximation of the median for each category was performed using the cohort and/or category range where available. For categories defined by numerical cutoffs of 25OHD, the median for the lower category was approximated as the lowest reported 25OHD value (or 0 if category range not given) added to the midpoint of the category upper cutoff minus the lowest reported 25OHD value. For example, Bittenbring *et al* ([@bib10]) reported outcome according to 25OHD \<\>8 ng ml^−1^ groups and reported a study cohort range of 4--61.9. The median of the lower category (\<8 ng ml^−1^) was approximated as the lowest value in the range plus the midpoint of the category that is, 4+((8−4)/2)=6. The upper category median was approximated as the category cutoff (that is, the lowest value in that category) added to the midpoint of the lower category. for example, in the Bittenbring *et al*, paper the median of the upper category was approximated as 8+((8−4)/2)=10. Where the compared categories were tertiles, quartiles or quintiles, the median of the lower category and upper categories was the midpoint of the difference between upper cutoff of the lower category compared and the lower cut-off of the higher category compared divided by the number of groups between two categories compared, either subtracted from the upper cutoff of the lower category or added to the lower cutoff of the higher category, respectively. For example, Bade *et al*, ([@bib8]) grouped patients by quartile of 25OHD and report a cohort range of 4--59.6 ng ml^−1^. Q1 is given as 25OHD\<9.86 ng ml^−1^ and Q4 \>24.4 ng ml^−1^. Therefore, the medians of Q1 and Q4 were approximated as follows: Q1(median)=9.86−(((24.4−9.86)/2)/2)=6.225 and Q4(median)=24.4+(((24.4−9.86)/2)/2)=28. Insufficient data were reported in three studies to allow graphical illustration of categories or approximation of median. NA=data not reported; For Tretli *et al*, study: B=breast; C=colon; L=lung; Ly=lymphoma.](bjc201744f2){#fig2}

![**Cancer survival and 25-hydroxyvitamin D concentration: meta-analysis of adjusted hazard ratios.**HR are sorted by cancer site and the difference in median between 'high\' and 'low\' vitamin D categories compared. Acute myeloid leukaemia (AML), Chronic Lymphoid Leukaemia (CLL), and subtypes of non- Hodgkin\'s lymphoma (NHL) (large B-cell lymphoma (DLBCL), T-cell lymphoma (TCL), Follicular Lymphoma (FL) and mantle cell lymphoma (MCL)) Myelodysplastic syndrome (MDS) and primary myelofibrosis (PMF). *I*^2^=breast: 0, haematological: 0, colorectal: 0.91, prostate: 0.68, head and neck: 0, pancreatic: 0.66, lung: 0.93, skin: 0, overall cancer: 0.18. Approximated Median in studies using quartiles/tertiles (ng ml^−1^): Tretli breast (lower: 12.9, upper: 33.9), Tretli Haematological: (lower:14.3, upper: 34.1), Tretli colorectal: (lower:16.4, upper: 38), Tretli lung: (lower:14.3, upper: 34.1), Vrieling: (lower: 10.6, upper: NA), [@bib57] (NA), Fedirko: (lower:11.8, upper: 33.4), [@bib83]: (lower:9.6, upper: 30.7), Zgaga: (lower:4.4, upper: 18.3), [@bib82]: (lower:21, upper: 30.6), Liu: (lower:7, upper: 25.4), Zhou: (lower:7.4, upper: 24.5), Heist: (lower:10.4, upper: 23.9), Meyer: (lower:16.2, upper: 34.2), Fang: (NA), Muller: (NA).](bjc201744f3){#fig3}

![**Cancer progression and 25-hydroxyvitamin D concentration: meta-analysis of adjusted hazard ratios.**HR are sortd by the difference in median between high and low vitamin D levels compared. Acute myeloid leukaemia (AML), Chronic Lymphoid Leukaemia (CLL), and subtypes of non- Hodgkin\'s lymphoma (NHL) (large B-cell lymphoma (DLBCL), T-cell lymphoma (TCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL)). I2=breast: 0, haematological: 0, colorectal: 0, head and neck: 0, skin: 0 overall cancer: 0. Approximated median in studies using quartiles/tertiles (ng ml^−1^): Vrieling: (lower: 10.6, upper: NA), Kelly (NA), Meyer: (lower:16.2, upper: 34.2), [@bib83]: (lower:9.6, upper: 30.7).](bjc201744f4){#fig4}

###### 

**Cancer survival and vitamin D receptor polymorphisms and other vitamin D-related genetic factors: adjusted meta-analysis.***I*^2^ for ApaI: 0.95, BsmI prostate: 0.93, BsmI Lung: 0.93, BsmI colorectal: 0, BsmI All: 0.85, Cdx2 prostate: 0, Cdx2 lung: 0, Cdx2 colorectal: 0, Cdx2 All: 0, FokI Prostate: 0, FokI lung: 0, FokI colorectal: 0, FokI All: 0.83, TaqI breast: 0.88, TaqI skin: 0.46, TaqI all: 0.86, Cyp24a1(1) all: 0.75, Cyp24a1(2) all: 0.67, GC all: 0, Rs2107301 all: 0, Rs4516035: 0, Rs2238135: 0.

![](bjc201744f5a)

![](bjc201744f5b)

![](bjc201744f5c)

![**Cancer progression and vitamin D receptor polymorphisms and other vitamin D-related genetic variants: adjusted meta-analysis.***I*^2^ for ApaI: 0, BsmI prostate: 0.52, BsmI breast: 0.1, BsmI All: 0.61, FokI Prostate: 0, FokI All: 0.90, TaqI all: 0, Rs4516035: 0.94, Rs22382679: 0.](bjc201744f6){#fig6}

###### Characteristics of studies (*N*=64) included in the meta-analysis

                                                                                                                                                     **Variable**   **Outcome**        
  ----------------------- ----------------------------------- ---- ------ ------------ --------- ---------------------------------------------- --- -------------- ------------- ----- ----
  [@bib5]                 Brain (glioma)                       HR  320        USA      28        248 cancer deaths                              5                        ✓              CS
  [@bib66]                Breast                               HR  491       Korea     86        32 recurrences; 22 cancer deaths               8        ✓ BT                     DFS   CS
  [@bib68]                Breast                               HR  934       Canada    112       Not given                                      4        ✓ BT                     RFS   OS
  [@bib16]                Breast                               HR  82         USA      \>36      23 relapses or deaths                          5        ✓ BT                     RFS    
  [@bib123]               Breast                               HR  2177     Germany    64        206 cancer deaths, 241 recurrences or deaths   7      ✓ 66% BT                   DFS   CS
  [@bib74]                Breast                               OR  232        USA      NA        Not given                                      5                        ✓        DFS    
  [@bib88]                Breast                               HR  1029       USA      114       266 recurrences or deaths                      6                        ✓        DFS    
  [@bib93]                Breast                               HR  498      Germany    60        48 cancer deaths                               7                        ✓              CS
  [@bib121]               Breast                               HR  585        USA      110       48 cancer deaths                               7        ✓ AT                           CS
  [@bib45]                Breast                               HR  1800     Belgium    56        118 relapses; 64 cancer deaths                 5        ✓ BT                     DFI   CS
  [@bib54]                Breast                               OR  512        USA      88        Not given                                      5        ✓ AT                      R    OS
  [@bib58]                Breast                               HR  310       Korea     23        33 metastases or deaths                        7        ✓ BT                     DFS    
  [@bib38]                Breast                               HR  512       Canada    139       116 recurrences; 106 deaths                    7        ✓ BT                      R    OS
  [@bib37]                Breast                               HR  721         UK      NA        200 deaths                                     6                        ✓              OS
  [@bib70]                Breast                               RR  111       Sweden    67        44 deaths                                      4                        ✓              OS
  [@bib113]               Breast, colon, lung, and lymphoma    HR  658       Norway    \>60      343 cancer deaths                              7        ✓ BT                           CS
  [@bib127]               Colorectal                           HR  250        USA      NA        153 deaths                                     5        ✓ BT                           OS
  [@bib137]               Colorectal                           HR  1598        UK      107       363 cancer deaths                              8        ✓ AT            ✓              CS
  [@bib94]                Colorectal                           HR  1397     Germany    60        336 cancer deaths                              6                        ✓              CS
  [@bib106]               Colorectal                           HR  264      Austria    53        45 recurrences                                 5                        ✓         R     
  [@bib32]                Colorectal                           HR  1202      Europe    73        444 cancer deaths                              8        ✓ BD            ✓              CS
  [@bib83]                Colorectal                           HR  515        USA      61        440 progression; 475 deaths                    5        ✓ BT                     TTP   OS
  [@bib73]                Colorectal                           HR  257       Japan     32        30 cancer deaths; recurrences not given        5        ✓ NS                     DFS   CS
  [@bib82]                Colorectal                           HR  304        USA      78        96 cancer deaths                               7        ✓ BD                           CS
  [@bib97]                Gastric                              HR  197       China     \>60      106 deaths                                     5        ✓ BT                           OS
  [@bib63]                Haematological (AML)                 HR  97         USA      16        55 relapses; 51 deaths                         4        ✓ BT                      R    OS
  [@bib100]               Haematological (CLL)                 HR  543        USA      118       201 progression; 96 deaths                     8        ✓ NS                     TTT   OS
  [@bib6]                 Haematological (CLL, NHL)            HR  195       Egypt     60        118 deaths                                     5        ✓ BT                           OS
  [@bib26]                Haematological (DLBCL)               HR  983        USA      35        404 events; 168 cancer deaths                  6      ✓ 66% BT                   EFF   CS
  [@bib90]                Haematological (PMF, MDS)            HR  321        USA      34        36 progression; 171 deaths                     4        ✓ BT                     LFS   OS
  [@bib10]                Haemotological (BCL)                 HR  359      Germany    49        Not given                                      4        ✓ AT                     EFF   OS
  [@bib56]                Haemotological (FL)                  HR  423        USA      65        193 progression; 58 deaths                     5        ✓ BT                     PFS   OS
  [@bib7]                 Head and neck                        HR  522       Canada    \>53      214 deaths                                     8                        ✓              OS
  [@bib136]               Head and neck                        OR  110       Serbia    28--100   Not given                                      5                        ✓              CS
  [@bib72]                Head and neck                        HR  540       Canada    96        119 recurrences; 223 deaths                    8        ✓ BT                      R    OS
  [@bib39]                Head and neck (SCC)                  RR  88       Austria    NA        31 progression; 29 deaths                      4        ✓ BT                     DFS   OS
  [@bib42]                Head and neck (SCC)                  HR  204       Japan     34        103 progression or deaths                      6                        ✓        DFS    
  [@bib34]                Liver (HCC)                          HR  200      Germany    11        60 deaths                                      6        ✓ BT                           OS
  [@bib140]               Lung                                 HR  447        USA      72        126 cancer deaths                              7        ✓ BT                           CS
  [@bib67]                Lung (AC, SCC)                       HR  568       China     19        311 deaths                                     6        ✓ NS            ✓              OS
  [@bib46]                Lung (AC, SCC)                       HR  294        USA      42        233 deaths                                     6        ✓ NS            ✓              OS
  [@bib141]               Lung (AC, SCC)                       HR  373        USA      71        186 deaths                                     7                        ✓              OS
  [@bib129]               Lung (NSCC)                          HR  755       China     NA        Not given                                      4                        ✓        PFS   OS
  [@bib81]                Melanoma                             HR  2182        UK      NA        Not given                                      6        ✓ NS                           CS
  Davies *et al* (2014)   Melanoma                             HR  3137     Various    96        653 deaths                                     7                        ✓              OS
  Orlow *et al* (2014)    Melanoma                             HR  3566    World wide  91        254 cancer deaths                              7                        ✓              CS
  [@bib80]                Melanoma                             HR  872         UK      56        173 relapses                                   5        ✓ NS                     DFS    
  [@bib41]                Melanoma                             HR  171         UK      75        18 metastases                                  4                        ✓         M     
  [@bib125]               Ovarian                              HR  670     Australia   \>60      491 progression; 435 deaths                    7        ✓ BT                     PFS   OS
  [@bib107]               Ovarian                              HR  101       Japan     85        28 cancer deaths; total deaths not given       7                        ✓              OS
  [@bib119]               Pancreatic                           HR  256       Europe    35        progression not given; 254 deaths              4        ✓ BT                     PFS   OS
  [@bib15]                Pancreatic                           HR  178        USA      33        82 deaths                                      5        ✓ BT                           OS
  [@bib40]                Prostate                             HR  125        USA      31        49 deaths                                      7        ✓ BT                           OS
  [@bib114]               Prostate                             HR  702      Austria    73--91    93 metastases; 123 deaths                      6                        ✓         M    OS
  [@bib50]                Prostate                             HR  1476       USA      130       325 progression; 95 cancer deaths              7        ✓ NS                      P    CS
  [@bib89]                Prostate                             HR  601       Taiwan    60--120   415 progression; 101 cancer deaths             8                        ✓         P    CS
  [@bib29]                Prostate                             HR  1822       USA      120       166 cancer deaths                              8        ✓ BD                           CS
  [@bib51]                Prostate                             HR  1294       USA      102       139 recurrences; 57 cancer deaths              8                        ✓         R    CS
  [@bib92]                Prostate                             OR  1292       USA      \>60      Not given                                      5                        ✓              OS
  [@bib112]               Prostate                             HR  160       Norway    44        52 cancer deaths                               6      ✓ 77% BT                         CS
  [@bib128]               Prostate                             HR  728        USA      60--120   Not given                                      7                        ✓        DFS    
                          Renal                                HR  630       Europe    30        152 cancer deaths                              8        ✓ BT                           CS
  [@bib85]                Renal (RCC)                          RR  135       Japan     \>60      Not given                                      5                        ✓              CS
  [@bib98]                Skin (Merkel cell)                   HR  89        France    NA        33 metastases; 19 deaths                       6        ✓ NS                      M    CS

Abbreviations: AC=adenocarcinoma; ALL=acute lymphocytic leukaemia; AML=acute myeloid leukaemia; AT 25OHD=assayed after cancer treatment; BCL=B-cell lymphoma; BD 25OHD=assayed before diagnosis; BT 25OHD=assayed before treatment; CML=chronic myeloid leukaemia; CS=cancer-specific survival; DFI=disease-free interval; DFS=disease-free survival; DLBCL diffuse large B-cell lymphoma; EFF=event-free survival; FL=follicular lymphoma; HCC=Hepatocellular carcinoma; LFS=leaukaemia-free survival; m months; M=metastasis; MDS=myelodysplastic syndrome; NA=not available; NHL=Non-Hodgkins lymphoma; NOS=Newcastle-Ottawa score; NS=Timing of 25OHD not specified/variable; NSCC=non-small-cell lung carcinoma; OS=overall-survival; P=progression not otherwise specified; PFS=progression-free survival; PMF=primary myelofibrosis; R=recurrence or relapse not otherwise specified; RCC=renal cell carcinoma; RFS=relapse/recurrence-free survival; SCC=squamous cell carcinoma; TTP=time to progression; TTT=time to treatment.

###### Characteristics of studies (*N*=17) included in the qualitative synthesis

                                                                                                                   **Variable**   **Outcome**                                                                                                                                             
  ----------- ------------------------------------- -------- ----- ------------------------------------------ --- -------------- ------------- ----- ---- ------------------------------------------------------------------------------------------------------------------------------ --------------------------
  [@bib86]    Colorectal                            84       24                    Not given                  4         ✓                       PFS   OS  Consistently low 25OHD (always \<16 ng/ml) associated with worse PFS and OS                                                    Serial 25OHD
  [@bib115]   Lung (NSCC)                           142      52                    Not given                  7                                       CS  Low serum DBP levels predicted lung cancer-specific death (*P*=0.04)                                                           Only paper reporting DBP
  [@bib116]   Lung(NSCC)                            62       NA                    Not given                  5                        ✓              OS  Haplotype analysis revealed rs731236 (*TaqI)*---rs2228570 (*FokI) TTFf/TtFf* haplotype associated with reduced OS (*P*=0.04)   No individual SNP HR
  [@bib8]     Melanoma                              324      NA                    Not given                  6         ✓                             OS  Increased 25OHD (Q4 v Q1) associated with increased OS 195 months v 80 months (*P*=0.049)                                      No HR
  [@bib23]    Prostate                              16 535   60                   4613 deaths                 5         ✓                             OS  Vitamin D deficiency significantly associated with reduced survival (\<0.001)                                                  No HR
  [@bib24]    Haematological (CML)                  228      NA              55 relapses; 84 deaths           5                        ✓         R    OS  No data provided on impact of *VDR* variants                                                                                   No HR
  [@bib36]    Prostate                              66       NA                    Not given                  3                        ✓        PFS       *TaqI TT* genotype associated with shorter PFS (*P*=0.07)                                                                      No HR
  [@bib44]    Haematological (AML, ALL, CML, MDS)   123      96              29 relapses; 31 deaths           6         ✓                        R    OS  25OHD \<20 ng/ml associated with reduced OS (*P*=0.01) and increased relapse (*P*=0.03)                                        No HR
  [@bib58]    Haematological                        100      105             12 relapses; 4 deaths            4                        ✓        EFS   OS  *VDR* rs2228570 *FokI* genotype did not impact survival in paediatric ALL                                                      No HR
  [@bib84]    Melanoma                              205      NA                  118 metastases               4         ✓                        M        25OHD \>20 ng/l associated with increased time to distant metastatic disease (*P*=0.64)                                        No HR
  [@bib91]    Bladder                               4126     NA                   2025 deaths                 6         ✓                             OS  25OHD \<20 ng/ml associated with reduced OS (X2=10.44; *P*=0.001)                                                              No HR
  [@bib101]   Ovarian (Epithelial)                  26       NA                    Not given                  2                        ✓              OS  Increased platelet VDR expression (\>50 fMol) associated with increased OS (*P*=0.12)                                          No HR
  [@bib124]   Ovarian                               72       60                    45 deaths                  6         ✓                             OS  25OHD \<10 ng/ml associated with reduced OS (*P*\<0.04)                                                                        No HR
  [@bib131]   Breast                                56       60                  5 recurrences                3                        ✓         R        *rs1544410 (BsmI)* genotype not associated with local recurrence or metastasis *P*\>0.05                                       No HR
  [@bib134]   Breast                                87       60                    Not given                  3                        ✓        PFS   OS  *rs2228570 FokI ff* associated with reduced PFS 35 months *vs* \>54 months (*P*=0.08)                                          No HR
  [@bib33]    Melanoma                              795      56                137 cancer deaths              4         ✓                             CS  8 ng/ml incremental increase in 25OHD associated with improved DFS (*P*=0.02) and MSS (*P*=0.05)                               Duplicate patient cohort
  [@bib122]   Breast                                1295     70     182 recurrence or metastases; 183 deaths  7         ✓                       DFS   OS  Low 25OHD significantly associated with worse DFS and OS                                                                       Duplicate patient cohort

Abbreviations: AML=acute myeloid leukaemia, ALL=acute lymphocytic leukaemia; CML=chronic myeloid leukaemia; CS=cancer-specific survival; DFS=disease-free survival; DBP=vitamin D binding protein; EFF=event-free survival; fMol=femtomol; HR=hazard ratio; m=months; M=metastasis; MDS=myelodysplastic syndrome; MSS=melanoma specific survival; NOS=Newcastle-Ottawa score; NSCC=non-small-cell lung carcinoma; OS=overall survival; PFS=progression-free survival; R=recurrence or relapse not otherwise specified; SNP=single nucleotide polymorphism.

###### Box 1.

Conversion of continuous HR and 95% CI estimate to per 10 ng ml^−1^ HR estimates.

To achieve this, we raised the continuous HR (or 'HR per 1 ng ml^−1^\') to the power of 10 to get *\[A\]*, per 10 ng ml^−1^ HR (e.g., continuous HR, 0.89, hence per 10 ng ml^−1^ HR: 0.89\^10=0.3118). In order to calculate the confidence intervals we first found the exp(s.e.(beta))=*\[B\]*; the standard errors (s.e.) were calculated using the formula below. We then calculated 1.96\*(x−xbar)=*\[C\]*, where x was fixed at 10 ng ml^−1^ and xbar was the median of all cohort means from the rest of the studies included in the meta-analysis. We found this to be 23 ng ml^−1^, therefore *1.96\*(10−23)=−25.872=\[C\]. \[B\]* was then raised to the power of *\[C\],* to get *\[D\].* Finally, the HR per 10 ng ml^−1^ *\[A\]* was multiplied or divided by *\[D\]* in order to derive the upper and lower 95% confidence intervals. Therefore, the resulting HR was *A* and 95% CI: (*A\*D*) to (*A/D*).

(Continuous HR)\^10=\[*A*\]=per 10 ng/ml HR

exp(s.e.(beta))=\[*B*\]

1.96\*(x−xbar)=\[*C*\]

*B*\^*C*=\[*D*\]

*A*\**D*=lower 95% CI

*A*/*D*=upper 95% CI.
